Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Global Forecast 2025-2030- Product Image

Sale

Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Global Forecast 2025-2030

Report
197 Pages
October 2024
Region: Global
360iResearch™
ID: 5666022

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The Cardiovascular Drugs Market grew from USD 82.65 billion in 2023 to USD 90.13 billion in 2024. It is expected to continue growing at a CAGR of 9.15%, reaching USD 152.61 billion by 2030.

The scope of the cardiovascular drugs market encompasses a wide array of medications used to treat diseases of the heart and blood vessels, including antihypertensives, antiarrhythmics, anticoagulants, and cholesterol-lowering drugs. These drugs are essential in managing conditions such as hypertension, heart failure, angina, arrhythmias, and high cholesterol, which are critical in reducing morbidity and mortality associated with cardiovascular diseases (CVDs). The application of these drugs spans hospitals, clinics, and home care settings, with end-users including patients, healthcare providers, and health insurance companies. Key growth drivers for the market include the rising prevalence of CVDs due to aging populations, lifestyle changes, and increasing awareness about heart health. Technological advancements and innovations like personalized medicine and drug delivery systems present substantial growth opportunities. For example, the use of AI and machine learning in drug discovery and development can facilitate more targeted therapies. Expanding healthcare access in emerging markets further presents untapped opportunities. However, market growth is tempered by challenges such as stringent regulatory requirements, high R&D costs, and potential side effects of drugs that necessitate vigilance and monitoring. Additionally, patent expirations of major drugs pose revenue challenges for branded drug manufacturers, leading to increased competition from generics. Innovation in biotechnology, focused on gene therapy and regenerative medicine, presents promising areas for research and development. Companies can focus on strategic partnerships and acquisitions to advance research and enhance their product pipelines. A continuous emphasis on diversification and differentiation, through targeting niche patient segments or exploring combo therapies, can offer growth pathways. Understanding the evolving healthcare policies and reimbursement challenges is vital for navigating the market effectively. Overall, the cardiovascular drugs market remains dynamic, with significant potential for growth and innovation, driven by an integrated approach towards research, market expansion, and patient-centric product development.

Understanding Market Dynamics in the Cardiovascular Drugs Market

The Cardiovascular Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising Prevalence of Cardiovascular Disorders
- Increasing R&D Investments for Drug Development
- Government Initiatives for Prevention & Control of Cardiovascular Diseases
Market Restraints
- Product Recalls and High Cost of Cardiovascular Drugs
Market Opportunities
- Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
- Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
Market Challenges
- Complexities in Efficient and Safe Drug Development

Exploring Porter’s Five Forces for the Cardiovascular Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Cardiovascular Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cardiovascular Drugs Market

External macro-environmental factors deeply influence the performance of the Cardiovascular Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cardiovascular Drugs Market

The Cardiovascular Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cardiovascular Drugs Market

The Cardiovascular Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Gilead Sciences, Inc., Otsuka Holdings Co., Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Chiesi USA, Inc., Cornerstone Therapeutics Inc., Pfizer Inc., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Ferring B.V., Sanofi S.A., Novo Nordisk A/S, Boehringer Ingelheim GmbH, Par Pharmaceutical by Endo International, CYTOKINETICS, Incorporated, Bristol-Myers Squibb Company, Bausch Health Companies Inc., Abbott Laboratories, Auro Pharma Inc., WellSpring Pharmaceutical Corporation, Merck KGaA, AstraZeneca PLC, Zydus Group, Baxter International Inc., Apotex Inc., Bayer AG, and Cipla Limited.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Angiotensin Inhibitors
- Anticoagulants
- Antihyperlipidemic
- Antihypertensive
- Antiplatelet Drugs
Disease Indication
- Arrhythmia
- Coronary Artery Disease
- Hyperlipidaemia
- Hypertension
Route of Administration
- Intravenous
- Oral
- Subcutaneous
Mode of Purchase
- Over-The-Counter Drugs
- Prescription-Based Drugs
End-Users
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Cardiovascular Disorders
5.1.1.2. Increasing R&D Investments for Drug Development
5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
5.1.2. Restraints
5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
5.1.3. Opportunities
5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
5.1.4. Challenges
5.1.4.1. Complexities in Efficient and Safe Drug Development
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Cardiovascular Drugs Market, by Drug Type

6.1. Introduction
6.2. Angiotensin Inhibitors
6.3. Anticoagulants
6.4. Antihyperlipidemic
6.5. Antihypertensive
6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

7.1. Introduction
7.2. Arrhythmia
7.3. Coronary Artery Disease
7.4. Hyperlipidaemia
7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
14.3.2. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
14.3.3. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

List of Figures

FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CARDIOVASCULAR DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 49. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 72. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 76. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 81. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 91. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 117. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 121. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 138. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 142. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 143. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 147. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 152. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 163. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 167. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 178. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 182. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 183. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 187. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 188. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 192. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 238. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 239. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cardiovascular Drugs market, which are profiled in this report, include:

Gilead Sciences, Inc.
Otsuka Holdings Co., Ltd.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
Chiesi USA, Inc.
Cornerstone Therapeutics Inc.
Pfizer Inc.
Daiichi Sankyo Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Eisai Co., Ltd.
Ferring B.V.
Sanofi S.A.
Novo Nordisk A/S
Boehringer Ingelheim GmbH
Par Pharmaceutical by Endo International
CYTOKINETICS, Incorporated
Bristol-Myers Squibb Company
Bausch Health Companies Inc.
Abbott Laboratories
Auro Pharma Inc.
WellSpring Pharmaceutical Corporation
Merck KGaA
AstraZeneca PLC
Zydus Group
Baxter International Inc.
Apotex Inc.
Bayer AG
Cipla Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 90.13 Billion
Forecasted Market Value ( USD ) by 2030	$ 152.61 Billion
Compound Annual Growth Rate	9.1%
Regions Covered	Global
No. of Companies Mentioned	31

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the Cardiovascular Drugs Market

Exploring Porter’s Five Forces for the Cardiovascular Drugs Market

Applying PESTLE Analysis to the Cardiovascular Drugs Market

Analyzing Market Share in the Cardiovascular Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cardiovascular Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Cardiovascular Therapeutics Market by Drug Class, Indication, Patient Demographics, End-User, Route of Administration, Distribution Channel - Global Forecast 2025-2030

Fibrate Drugs Market by Drug Type, Application, Patient Demographics, Distribution Channel, Formulation, End User, Route Of Administration, Mode Of Purchase - Global Forecast 2025-2030

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Beta Blockers, Sodium Channel Blockers), Route of Administration (Oral, Parenteral), Distribution Channel, Region, and Segment Forecasts, 2024-2030

Coronary Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030

Myocardial Infarction Global Market Report 2024

About the Cardiovascular Drugs Market